February 25, 2017 1:27 PM ET


Company Overview of AdAlta Limited

Company Overview

AdAlta Limited develops biological drugs for the treatment of underserved chronic diseases. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary (lung) fibrosis and other fibrotic diseases. AdAlta Limited was incorporated in 2006 and is headquartered in Melbourne, Australia.

15/2 Park Drive


Melbourne, VIC 3083


Founded in 2006


61 3 9479 5159

Key Executives for AdAlta Limited

Chief Executive Officer, Managing Director and Executive Director
Total Annual Compensation: A$151.4K
Compensation as of Fiscal Year 2016.

AdAlta Limited Key Developments

AdAlta Limited Reports Audited Consolidated Earnings Results for the Half Year Ended December 31, 2016

AdAlta Limited reported audited consolidated earnings results for the half year ended December 31, 2016. For the period, revenue was AUD 12,580 against AUD 4,807 a year ago. Loss before income tax was AUD 2,265,692 against AUD 688,415 a year ago. Loss for the period attributable to Owners of AdAlta Limited was AUD 2,265,692 against AUD 688,415 a year ago. Basic and diluted loss per share was 0.028 cents against 0.33 cents a year ago. Net cash used in operating activities was AUD 1,180,583 against AUD 131,689 a year ago.

AdAlta Limited Announces Positive Pre-Clinical Data Showing Drug Candidate Has Broad Fibrosis Treatment Potential

AdAlta Limited announced additional positive pre-clinical data for its lead drug candidate AD-114, a novel first-in-class drug candidate being developed to treat fibrosis, a condition prevalent in 45% to 50% of all diseases. The new data show the administration of AD-114 reduced fibrosis in therapeutic mouse models of both lung and liver fibrosis. In the mouse model of lung fibrosis, collagen deposition and collagen gene expression were both reduced in the lungs, after 14-days of i-body AD-114 treatment. Excessive collagen stiffens tissue, causing fibrosis. In the mouse model of liver fibrosis, serum alanine aminotransferase (ALT) levels and the non-alcoholic fatty liver disease (NAFLD) score were improved with the treatment of AD-114 for 21 days. Concentration of ALT in plasma is a biomarker for liver disease progression: the improvement in serum liver enzyme ALT levels suggests that the i-body ameliorated liver injury and inflammation. The NAFLD score improvement indicates AD-114 possesses hepatoprotective effects and therefore has potential for the treatment of non-alcoholic steatohepatitis (NASH). Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data. These new data validates a number of earlier studies and AdAlta has now demonstrated anti-fibrotic activity of AD-114 in animal models of lung, liver and eye fibrosis.

Adalta Limited Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Adalta Limited Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
AbRegen Pty Ltd. Asia
Advanced Wound Care Pty Ltd. Asia
Agriliance Pty Ltd. Asia
AION Diagnostics Limited Asia
Aquaceutics Pty Ltd Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AdAlta Limited, please visit www.adalta.com.au. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.